FDA Grants Crizotinib Breakthrough Designation for MET+ NSCLC and ALK+ ALCL

May 29, 2018 – The FDA has granted crizotinib a breakthrough therapy designation for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) with MET exon 14 alterations who progress after receiving platinum-based chemotherapy. The agency also granted the designation to the kinase inhibitor for use in patients with relapsed/refractory ALK+ anaplastic large cell lymphoma (ALCL). The breakthrough designation will expedite the development … (leggi tutto)